Mesalazine (5-aminosalicylic acid) induced chronic hepatitis

Gut

Volumn 44, Issue 6, 1999, Pages 886-888

  Deltenre, P ^a   Berson, A ^a   Marcellin, P ^a   Degott, C ^a   Biour, M ^b   Pessayre, D ^a,c  

^a BEAUJON HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c ENSERM U481   (France)

Author keywords

5 aminosalicylic acid; Adverse drug reaction; Chronic hepatitis; Hepatotoxicity; Liver; Mesalazine

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; AUTOANTIBODY; IMMUNOGLOBULIN G; LIVER ENZYME; MESALAZINE; SILICON DIOXIDE; SIMVASTATIN; SMOOTH MUSCLE ANTIBODY; SULFAPYRIDINE;

AGED; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; CROHN DISEASE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; HUMAN; MALE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0033014484     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.44.6.886     Document Type: Article

References (13)

1. Hayllar J, Bjarnason I. Suphasalazine in ulcerative colitis: in memoriam? Gut 1991;32:462-3.
2. Das KM, Eastwood MA, McManus JPA, et al. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973;289:491-5.
3. Sotolongo RP, Neefe LY, Rudzki C, et al. Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity. Gastroenterology 1978;75;95-9.
4. Farrell G. Drug-initiated liver disease. London: Churchill-Livingstone, 1994.
5. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. BMJ 1989;298:82-6.
6. Hautekeete ML, Bourgeois N, Potvin P, et al. Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine. Gastroenterology 1992;103:1925-7.
7. Coumaros D, Georges C, Zerbe S. Salicylazosulfapyridine (SASP) hepatitis: role of 5-aminosalicylic acid (5-ASA). Scand J Gastroenterol 1989;24(suppl 158):132-3.
8. Stochus B, Meybehm M, Spengler U, et al. Cholestasis associated with mesalazine therapy in a patient with Crohn's disease. J Hepatol 1997;26:425-8.
9. Kristensen KS, Hoegholm A, Bohr L, et al. Fatal myocarditis associated with mesalazine. Lancet 1990;335:605.
10. Woodward DK. Peripheral neuropathy and mesalazine. BMJ 1989;229:1224.
11. Deprez P, Descamps C, Fiasse R. Pancreatitis induced by 5-aminosalicylic acid. Lancet 1989;2;445-6.
12. Biour M, Poupon R, Grange JD, et al. Hepatotoxicité des médicaments. Onzíèrne míse à mise à jour du fichier bibliographique des atteintes hépatiques et des médicaments responsables. Gastroenterol Clin Biol (in press).
13. Rasmussen SN, Bondesen S, Hvidberg EF, et al. 5-Aminosalicylic acid in slow release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology 1982;83:1062-70.